Genetic vaccination for reestablishing T-cell tolerance in type 1 diabetes

Human Vaccines

Volumn 7, Issue 1, 2011, Pages 27-36

  Johnson, Mark C ^a   Wang, Bo ^a   Tisch, Roland ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Autoimmunity; Gene transfer; Immunoregulation; Plasmid DNA; Viral vectors

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; AUTOANTIGEN; CYTOKINE; DNA VACCINE; GLUTAMATE DECARBOXYLASE 65; GOLD; HEAT SHOCK PROTEIN 60; LIPOSOME; MICROSPHERE; MYELIN BASIC PROTEIN; PLASMID DNA; POLYMER; PROINSULIN; VIRUS VECTOR; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DIABETES MELLITUS; DIABETOGENESIS; ELECTROPORATION; GENE GUN IMMUNIZATION; GENE TRANSFER; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; STREPTOZOCIN DIABETES; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION; VACCINE PRODUCTION; ADENO ASSOCIATED VIRUS; ANIMAL; GENE THERAPY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MEDICAL RESEARCH; METHODOLOGY; PLASMID;

ANIMALS; AUTOIMMUNE DISEASES; BIOMEDICAL RESEARCH; DEPENDOVIRUS; DIABETES MELLITUS, TYPE 1; GENE THERAPY; IMMUNOTHERAPY; MODELS, ANIMAL; PLASMIDS; T-LYMPHOCYTES; VACCINATION; VACCINES;

EID: 79551698049     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.1.12848     Document Type: Review

References (155)

1. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23:447-85. (Pubitemid 40563177)
2. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994; 15:516-42.
3. Eisenbarth GS. Prediction of type 1 diabetes: the natural history of the prediabetic period. Adv Exp Med Biol 2004; 552:268-90. (Pubitemid 40090330)
4. Tisch R, McDevitt HO. Insulin-dependent diabetes mellitus. Cell 1996; 85:291-7. (Pubitemid 26160699)
5. Bendelac A, Carnaud C, Boitard C, Bach JF. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med 1987; 166:823-32. (Pubitemid 18024228)
6. + T-cells from diabetic versus prediabetic NOD.NONThy-1a donors. Diabetes 1993; 42:44-55.
7. + T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 1988; 140:52-8.
8. Standifer NE, Burwell EA, Gersuk VH, Greenbaum CJ, Nepom GT. Changes in autoreactive T cell avidity during type 1 diabetes development. Clin Immunol 2009; 132:312-20.
9. + T cells specific for different islet cell-associated epitopes using combinatorial MHC-multimers. Diabetes 2010; [Epub ahead of print].
10. Coppieters KT, von Herrath MG. Histopathology of type 1 diabetes: old paradigms and new insights. Rev Diabet Stud 2009; 6:85-96.
11. Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004; 113:451-63. (Pubitemid 38544189)
12. Todd JA, Wicker LS. Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models. Immunity 2001; 15:387-95. (Pubitemid 32907386)
13. Sarvetnick N. Etiology of autoimmunity. Immunol Res 2000; 21:357-62.
14. Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol 2001; 2:797-801.
15. Tisch R, Wang B. Dysregulation of T peripheral tolerance in type 1 diabetes. Adv Immunol 2008; 100:125-49.
16. + T-cells in type 1 diabetes. Diabetes 2005; 54:1407-14.
17. Fox CJ, Danska JS. IL-4 expression at the onset of islet inflammation predicts nondestructive insulitis in nonobese diabetic mice. J Immunol 1997; 158:2414-24. (Pubitemid 127470029)
18. Gregori S, Giarratana N, Smiroldo S, Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol 2003; 171:4040-7. (Pubitemid 37238678)
19. + T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med 2004; 199:1479-89.
20. + T-cells from patients with type 1 diabetes. Diabetes 2005; 54:92-9.
21. + regulatory T cells during autoimmune diabetes. J Exp Med 2005; 201:1333-46.
22. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006; 25:195-201. (Pubitemid 44224153)
23. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692-8. (Pubitemid 34547482)
24. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598-608. (Pubitemid 41007846)
25. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54:1763-9.
26. Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366:69-72. (Pubitemid 23345238)
27. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993; 366:72-5. (Pubitemid 23345239)
28. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998; 47:894-9. (Pubitemid 28255662)
29. Fife BT, Guleria I, Gubbels-Bupp M, Eagar TN, Tang Q, Bour-Jordan H, et al. Insulin-induced remission in new onset NOD mice is maintained by the PD-1-PDL1 pathway. J Exp Med 2006; 203:2737-47. (Pubitemid 44833349)
30. Muir A, Peck A, Clare-Salzler M, Song YH, Cornelius J, Luchetta R, et al. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J Clin Invest 1995; 95:628-34.
31. Coon B, An LL, Whitton JL, von Herrath MG. DNA immunization to prevent autoimmune diabetes. J Clin Invest 1999; 104:189-94.
32. Harrison LC, Honeyman MC, Steele CE, Stone NL, Sarugeri E, Bonifacio E, et al. Pancreatic beta cell function and immune response to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004; 27:2348-55. (Pubitemid 39281384)
33. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005; 28:1068-76. (Pubitemid 40616615)
34. Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010; 34:408-15.
35. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359:1909-20.
36. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Eng J Med 2002; 346:1685-91.
37. Liblau RS, Pearson CI, Shokat K, Tisch R, Yang XD, McDevitt HO. High-dose soluble antigen: peripheral T-cell proliferation or apoptosis. Immunol Rev 1994; 142:193-208.
38. Tisch R, McDevitt HO. Antigen-specific immunotherapy: is it a real possibility to combat T-cell-mediated autoimmunity? Proc Natl Acad Sci USA 1994; 91:437-8.
39. Harrison LC, Hafler DA. Antigen-specific therapy for autoimmune disease. Curr Opin Immunol 2000; 12:704-11.
40. Fousteri G, Bresson D, von Herrath M. Rational development of antigen-specific therapies for type 1 diabetes. Adv Exp Med Biol 2007; 601:313-9.
41. Luo X, Herold KC, Miller SD. Immunotherapy of Type 1 diabetes: Where are we and where should we be going? Immunity 2010; 32:488-99.
42. Wang B, Tisch R. Parameters influencing antigenspecific immunotherapy for Type 1 diabetes. Immunol Res 2008; 42:246-58.
43. Staeva-Vieira T, Peakman M, von Herrath M. Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007; 148:17-31. (Pubitemid 46364996)
44. Tian J, Kaufman DL. Antigen-based therapy for the treatment of type 1 diabetes. Diabetes 2009; 58:1939-46.
45. Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178:87-99. (Pubitemid 23173245)
46. Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71:169-75. (Pubitemid 24147233)
47. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, et al. Central role of defective interleukin-2 production in triggering islet autoimmune destruction. Immunity 2008; 28:687-97.
48. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22:531-62.
49. Haller MJ, Gottlieb PA, Schatz DA. Type 1 diabetes intervention trials 2007: where are we and where are we going? Curr Opin Endocrinol Diabetes Obes 2007; 14:283-7.
50. Bougneres PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C, et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990; 39:1264-72. (Pubitemid 20327064)
51. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhi E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54:2060-9. (Pubitemid 40911269)
52. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 1989; 320:550-4. (Pubitemid 19070538)
53. Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol 2005; 175:633-9. (Pubitemid 41094942)
54. Lu S, Wang S, Grimes-Serrano JM. Current Progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008; 7:175-91. (Pubitemid 351357954)
55. Garren H, Steinman L. DNA vaccination in the treatment of autoimmune disease. In: Fathman CG, editor, Biologic and Gene Therapy of Autoimmune Disease. Basel: Karger 2000; 203-16.
56. Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008; 42:219-32.
57. Williams JA, Carnes AE, Hodgson CP. Plasmid DNA vaccine vector design: Impact on efficacy, safety and upstream production. Biotech Adv 2009; 27:353-70.
58. Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997; 158:2278-84. (Pubitemid 127470012)
59. Weiss R, Scheiblhofer S, Freund J, Ferreira F, Livey I, Thalhamer J. Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine 2002; 20:3148-54.
60. Goudy KS, Wang B, Tisch R. Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes on nonobese diabetic mice. Clin Immunol 2008; 129:49-57.
61. Ewert KK, Ahmad A, Bouxsein NF, Evans HM, Safinya CR. Non-viral gene delivery with cationic liposome-DNA complexes. Methods Mol Biol 2008; 433:159-75.
62. Bodles-Brakhop AM, Heller R, Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther 2009; 17:585-92.
63. Shigihara T, Shimada A, Oikawa Y, Yoneyama H, Kanazawa Y, Okubo Y, et al. CXCL10 DNA vaccination prevents spontaneous diabetes through enhanced β cell proliferation in NOD mice. J Immunol 2005; 175:8401-8. (Pubitemid 41798407)
64. Meagher C, Arreaza G, Peters A, Strathdee CA, Gilbert PA, Mi QS, et al. CCL4 protects from Type 1 diabetes by altering islet β cell-targeted inflammatory responses. Diabetes 2007; 56:809-17. (Pubitemid 46348453)
65. Cameron MJ, Strathdee CA, Holmes KD, Arreaza GA, Dekaban GA, Delovitch TL. Biolistic-mediated interleukin 4 gene transfer prevents onset of Type 1 diabetes. Human Gene Ther 2000; 11:1647-56.
66. Nitta Y, Tashiro F, Tokui M, Shimada A, Takei I, Tabayashi K, et al. Systemic delivery of interleukin 10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice. Human Gene Ther 1998; 9:1701-7. (Pubitemid 28418740)
67. Tisch R, Wang B, Weaver DJ, Liu B, Bui T, Arthos J, Serreze DV. Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J Immunol 2001; 166:2122-32. (Pubitemid 32114703)
68. Seifarth C, Pop S, Liu B, Wong CP, Tisch R. More stringent conditions of plasmid DNA vaccination are required to protect grafted versus endogenous islets in nonobese diabetic mice. J Immunol 2003; 171:469-76. (Pubitemid 36745322)
69. + T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice. Diabetes 2007; 56:1395-402.
70. Piccirillo CA, Chang Y, Prud'homme GJ. TGFβ1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice. J Immunol 1998; 161:3950-6. (Pubitemid 28468971)
71. Prud'homme GJ, Chang Y. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Ther 1999; 6:771-7.
72. Weaver DJ, Liu B, Tisch R. Plasmid DNAs encoding insulin and glutamic acid decarboxylase 65 have distinct effects on the progression of autoimmune diabetes in nonobese diabetic mice. J Immunol 2001; 167:586-92. (Pubitemid 32567827)
73. Bot A, Smith D, Bot S, Hughes A, Wolfe T, Wang L, et al. Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J Immunol 2001; 167:2950-5. (Pubitemid 32768931)
74. Urbanek-Ruiz I, Ruiz PJ, Paragas V, Garren H, Steinman L, Fathman CG. Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice. Clin Immunol 2001; 100:164-71.
75. Solvason N, Lou YP, Peters W, Evans E, Martinez J, Ramirez U, et al. Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. J Immunol 2008; 181:8298-307.
76. + T cells that prevent experimental autoimmune diabetes. J Immunol 2006; 176:4608-15.
77. Quintana FJ, Rotem A, Carmi P, Cohen IR. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60 kDa heat shock protein autoimmunity. J Immunol 2000; 165:6148-55.
78. Glinka Y, De PR, Croze F, Prud'homme GJ. Regulatory cytokine production stimulated by DNA vaccination against an altered form of glutamic acid decarboxylase 65 in nonobese diabetic mice. J Mol Med 2003; 81:175-84. (Pubitemid 36470184)
79. Filippova M, Liu J, Escher A. Effects of plasmid DNA injection on cyclophosphamide-accelerated diabetes in NOD mice. DNA Cell Biol 2001; 20:175-81. (Pubitemid 34248246)
80. Wolfe T, Bot A, Hughes A, Mohrle U, Rodrigo E, Jaume JC, et al. Endogenous expression levels of autoantigens influence success or failure of DNA immunizations to prevent type 1 diabetes: addition of IL-4 increases safety. Eur J Immunol 2002; 32:113-21. (Pubitemid 34092828)
81. Glinka Y, Chang Y, Prud'homme GJ. Protective regulatory T cell generation in autoimmune diabetes by DNA covaccination with islet antigens and selective CTLA-4 ligand. Mol Ther 2006; 578-87.
82. Kaplan DH, Jenison MC, Saeland S, Shlomchik WD, Shlomchik MJ. Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 2005; 23:611-20. (Pubitemid 41779483)
83. Li AF, Escher A. Intradermal or oral delivery of GAD-encoding genetic vaccines suppress type 1 diabetes. DNA Cell Biol 2003; 22:227-32. (Pubitemid 36667850)
84. th Annual Meeting of the American Diabetes Association; June 5-9; New Orleans LA 2009.
85. Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nature Rev 2010; 8:62-73.
86. Lasaro MO, Ertl HCJ. New insights on adenovirus as vaccine vectors. Mol Ther 2009; 17:1333-9.
87. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Micro Rev 2008; 21:583-93.
88. Gray SJ, Samulski RJ. Optimizing gene delivery vectors for the treatment of heart disease. Expert Opin Biol Ther 2008; 8:911-22. (Pubitemid 352007003)
89. Smith RH. Adeno-associated virus integration: virus versus vector. Gene Ther 2008; 15:817-22. (Pubitemid 351712614)
90. Mueller C, Flotte TR. Clinical therapy using recombinant adeno-associated virus vectors. Gene Ther 2008; 15:858-63. (Pubitemid 351712619)
91. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Secondstrand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70:3227-34. (Pubitemid 26121941)
92. Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003; 10:2105-11. (Pubitemid 37536759)
93. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003; 10:2112-8. (Pubitemid 37536760)
94. McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther 2008; 16:1648-56.
95. Han G, Li Y, Wang J, Wang R, Chen G, Song L, et al. Active tolerance induction and prevention of autoimmune diabetes by immunogene therapy using recombinant adenoassociated virus expressing glutamic acid decarboxylase 65 peptide GAD(500-585). J Immunol 2005; 174:4516-24.
96. Han G, Wang R, Chen G, Wang J, Xu R, Feng J, et al. Gene delivery GAD 500 autoantigen by AAV serotype 1 prevented diabetes in NOD mice: transduction efficiency do not play important roles. Immunol Lett 2008; 115:110-6.
97. Jindal RM, Karanam M, Shah R. Prevention of diabetes in the NOD mouse by intra-muscular injection of recombinant adeno-associated virus containing the preproinsulin II gene. Int J Exp Diabetes Res 2001; 2:129-38.
98. Goudy K, Song S, Wasserfall C, Zhang YC, Kapturczak M, Muir A, et al. Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc Natl Acad Sci USA 2001; 98:13913-8. (Pubitemid 33115998)
99. + cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. J Immunol 2003; 171:2270-8.
100. Yang Z, Chen M, Wu R, Fialkow LB, Bromberg JS, McDuffie M, et al. Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol 2002; 168:6479-85. (Pubitemid 34620073)
101. Zhang YC, Pileggi A, Agarwal A, Molano RD, Powers M, Brusko T, et al. Adeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice. Diabetes 2003; 52:708-16. (Pubitemid 36323578)
102. Song S, Goudy K, Campbell-Thompson M, Wasserfall C, Scott-Jorgensen M, Wang J, et al. Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther 2004; 11:181-6. (Pubitemid 38159690)
103. Hu CM, Lin HH, Chiang MT, Chang PF, Chau LY. Systemic expression of heme oxygenase-1 ameliorates type 1 diabetes in NOD mice. Diabetes 2007; 56:1240-7.
104. Grimstein C, Choi YK, Satoh M, Lu Y, Wang X, Campbell-Thompson M, et al. Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis. J Gene Med 2010; 12:35-44.
105. Wang Z, Zhu T, Rehman KK, Bertera S, Zhang J, Chen C, et al. Widespread and stable pancreatic gene transfer by adeno-associated virus vectors via different routes. Diabetes 2006; 55:875-84. (Pubitemid 44100159)
106. Flotte T, Agarwal A, Wang J, Song S, Fenjves ES, Inverardi L, et al. Efficient ex vivo transduction of pancreatic islet cells with recombinant adeno-associated virus vectors. Diabetes 2001; 50:515-20. (Pubitemid 32195215)
107. Kapturczak M, Zolotukhin S, Cross J, Pileggi A, Molano RD, Jorgensen M, et al. Transduction of human and mouse pancreatic islet cells using a bicistronic recombinant adeno-associated viral vector. Mol Ther 2002; 5:154-60. (Pubitemid 34144831)
108. Prasad KM, Yang Z, Bleich D, Nadler JL. Adeno-associated virus vector mediated gene transfer to pancreatic beta cells. Gene Ther 2000; 7:1553-61.
109. Rehman KK, Wang Z, Bottino R, Balamurugan AN, Trucco M, Li J, et al. Efficient gene delivery to human and rodent islets with double-stranded (ds) AAV-based vectors. Gene Ther 2005; 12:1313-23. (Pubitemid 43084487)
110. Michelfelder S, Kohlschutter J, Skorupa A, Pfennings S, Muller O, Kleinschmidt JA, et al. Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries. PLoS One 2009; 4:5122.
111. Muller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 2003; 21:1040-6. (Pubitemid 37064733)
112. Work LM, Buning H, Hunt E, Nicklin SA, Denby L, Britton N, et al. Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther 2006; 13:683-93.
113. Dodiya HB, Bjorklund T, Stansell J, 3rd, Mandel RJ, Kirik D, Kordower JH. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther 2010; 18:579-87.
114. Grimm D, Zhou S, Nakai H, Thomas CE, Storm TA, Fuess S, et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 2003; 102:2412-9. (Pubitemid 37193577)
115. Rebuffat A, Harding CO, Ding Z, Thony B. Comparison of adeno-associated virus pseudotype 1, 2 and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria. Hum Gene Ther 2010; 21:463-77.
116. Rehman KK, Trucco M, Wang Z, Xiao X, Robbins PD. AAV8-mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice. Mol Ther 2008; 16:1409-16.
117. Riedel MJ, Gaddy DF, Asadi A, Robbins PD, Kieffer TJ. DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes. Gene Ther 2010; 17:171-80.
118. Giannoukakis N, Trucco M. Gene therapy for type 1 diabetes. Am J Ther 2005; 12:512-28. (Pubitemid 41689752)
119. Crooke ST. Progress in antisense technology. Annu Rev Med 2004; 55:61-95. (Pubitemid 38316716)
120. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol 2010; 50:259-93.
121. Machen J, Harnaha J, Lakomy R, Styche A, Trucco M, Giannoukakis N. Antisense oligonucleotides downregulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol 2004; 173:4331-41. (Pubitemid 39280661)
122. Phillips B, Nylander K, Harnaha J, Machen J, Lakomy R, Styche A, et al. A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes 2008; 57:1544-55.
123. Garren H. A DNA vaccine for multiple sclerosis. Expert Opin Biol Ther 2008; 8:1539-49.
124. Ranasinghe C, Ramshaw IA. Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity. Expert Rev Vaccines 2009; 8:1171-81.
125. Bresson D, Fradkin M, Manenkova Y, Rottembourg D, von Herrath M. Genetic-induced variations in the GAD65 T cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes. Mol Ther 2010; 18:307-16.
126. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9:1202-8. (Pubitemid 37173706)
127. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158:2947-54. (Pubitemid 127470558)
128. Ko KS, Lee M, Koh JJ, Kim SW. Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic miice. Mol Ther 2001; 4:313-6. (Pubitemid 33040515)
129. Balasa B, Boehm BO, Fortnagel A, Karges W, Van Gunst K, Jung N, et al. Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection. Clin Immunol 2001; 99:241-52.
130. Glinka Y, Pooter R, Croze F, Prud'homme GJ. Regulatory cytokine production stimulated by DNA vaccination against an altered form of glutamic acid decarboxylase 65 in nonobese diabetic mice. J Mol Med 2003; 81:175-84. (Pubitemid 36470184)
131. Prud'homme GJ, Chang Y, Li X. Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand. Human Gene Ther 2002; 13:395-406.
132. + regulatory T cells in vitro. Vaccine 2006; 24:5036-46.
133. Yamada K, Moriyama H, Okumachi Y, Arai T, Kameno M, Kishi M, et al. Intravenous administration of proinsulin 1 or 2-expressing fiber-mutant recombinant adenovirus vector protects against the development of diabetes in NOD mice. Ann NY Acad Sci 2008; 1150:183-6.
134. Fernandes JR, Duvivier-Kali VF, Keegan M, Hollister-Lock J, Omer A, Su S, et al. Transplantation of islets transduced with CTLA4-Ig and TGFbeta using adenovirus and lentivirus vectors. Transpl Immunol 2004; 13:191-200. (Pubitemid 39285976)
135. Park L, Lee E, Lee S, Lim M, Hong H, Shin G, et al. TGFbeta plasmid construction and delivery for the prevention of type 1 diabetes. Ann N Y Acad Sci 2008; 1150:177-82.
136. + regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice. Transplantation 2005; 79:1091-6.
137. Sakata M, Yasuda H, Moriyama H, Yamada K, Kotani R, Kurohara M, et al. Prevention of recurrent but not spontaneous autoimmune diabetes by transplanted NOD islets adenovirally transduced with immunomodulating molecules. Diabetes Res Clin Pract 2008; 80:352-9.
138. Yasuda H, Nagata M, Arisawa K, Yoshida R, Fujihira K, Okamoto N, et al. Local expression of immunoregulatory IL-12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice. J Clin Invest 1998; 102:1807-14. (Pubitemid 28533827)
139. Smith DK, Korbutt GS, Suarez-Pinzon WL, Kao D, Rajotte RV, Elliott JF. Interleukin-4 or interleukin-10 expressed from adenovirus-transduced syngeneic islet grafts fails to prevent beta cell destruction in diabetic NOD mice. Transplantation 1997; 64:1040-9. (Pubitemid 27446771)
140. Cameron MJ, Arreaza GA, Waldhauser L, Gauldie J, Delovitch TL. Immunotherapy of spontaneous type 1 diabetes in nonobese diabetic mice by systemic interleukin-4 treatment employing adenovirus vector-mediated gene transfer. Gene Ther 2000; 7:1840-6.
141. Alexander AM, Crawford M, Bertera S, Rudert WA, Takikawa O, Robbins PD, et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 2002; 51:356-65. (Pubitemid 34764790)
142. Panakanti R, Mahato RI. Bipartite vector encoding hVEGF and hIL-1Ra for ex vivo transduction into human islets. Mol Pharm 2009; 6:274-84.
143. Panakanti R, Mahato RI. Bipartite adenoviral vector encoding hHGF and hIL-1Ra for improved human islet transplantation. Pharm Res 2009; 26:587-96.
144. Narang AS, Sabek O, Gaber AO, Mahato RI. Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function 2006; 23:1970-82.
145. Kawamoto K, Tanemura M, Komoda H, Omori T, Fumimoto Y, Shimada K, et al. Adenoviral-mediated overexpression of membrane-bound human FasL and human decoy Fas protect pig islets against human CD8+ CTL-mediated cytotoxicity. Transplant Proc 2006; 38:3286-8. (Pubitemid 44908457)
146. Kawamoto K, Tanemura M, Saga A, Komoda H, Fumimoto Y, Deguchi T, et al. Adenoviral-mediated overexpression of either membrane-bound human FasL or human decoy Fas can prolong pig islet xenograft survival in a rat transplant model. Transplant Proc 2008; 40:477-9. (Pubitemid 351406413)
147. Giannoukakis N, Mi Z, Rudert WA, Gambotto A, Trucco M, Robbins P. Prevention of beta cell dysfunction and apoptosis activation in human islets by adenoviral gene transfer of the insulin-like growth factor I. Gene Ther 2000; 7:2015-22. (Pubitemid 32036767)
148. Zhang YC, Molano RD, Pileggi A, Powers M, Cross J, Wasserfall C, et al. Adeno-associated virus transduction of islets with interleukin-4 results in impaired metabolic function in syngeneic marginal islet mass transplantation. Transplantation 2002; 74:1184-6. (Pubitemid 35216116)
149. Zhang YC, Pileggi A, Molano RD, Wasserfall C, Campbell-Thompson M, Ricordi C, et al. Systemic overexpression of interleukin-10 fails to protect allogeneic islet transplants in nonobese diabetic mice. Transplantation 2005; 80:530-3. (Pubitemid 41209423)
150. Carter JD, Ellett JD, Chen M, Smith KM, Fialkow LB, McDuffie MJ, et al. Viral IL-10-mediated immune regulation in pancreatic islet transplantation. Mol Ther 2005; 12:360-8. (Pubitemid 41025108)
151. Oh TK, Li MZ, Kim ST. Gene therapy for diabetes mellitus in rats by intramuscular injection of lentivirus containing insulin gene. Diabetes Res Clin Pract 2006; 71:233-40.
152. Gallichan WS, Kafri T, Krahl T, Verma IM, Sarvetnick N. Lentivirus-mediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulitis. Hum Gene Ther 1998; 18:2717-26. (Pubitemid 29027015)
153. Chou FC, Sytwu HK. Overexpression of thioredoxin in islets transduced by a lentiviral vector prolongs graft survival in autoimmune diabetic NOD mice. J Biomed Sci 2009; 16:71.
154. Giannoukakis N, Mi Z, Gambotto A, Eramo A, Ricordi C, Trucco M, et al.
155. Fenjves ES, Ochoa MS, Cechin S, Gay-Rabinstein C, Pérez-Alvarez I, Ichii H, et al. Protection of human pancreatic islets using a lentiviral vector expressing two genes: cFLIP and GFP. Cell Transplant 2008; 17:793-802.